Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cancer Cell ; 42(7): 1239-1257.e7, 2024 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-38942025

RESUMEN

Global investigation of medulloblastoma has been hindered by the widespread inaccessibility of molecular subgroup testing and paucity of data. To bridge this gap, we established an international molecularly characterized database encompassing 934 medulloblastoma patients from thirteen centers across China and the United States. We demonstrate how image-based machine learning strategies have the potential to create an alternative pathway for non-invasive, presurgical, and low-cost molecular subgroup prediction in the clinical management of medulloblastoma. Our robust validation strategies-including cross-validation, external validation, and consecutive validation-demonstrate the model's efficacy as a generalizable molecular diagnosis classifier. The detailed analysis of MRI characteristics replenishes the understanding of medulloblastoma through a nuanced radiographic lens. Additionally, comparisons between East Asia and North America subsets highlight critical management implications. We made this comprehensive dataset, which includes MRI signatures, clinicopathological features, treatment variables, and survival data, publicly available to advance global medulloblastoma research.


Asunto(s)
Neoplasias Cerebelosas , Imagen por Resonancia Magnética , Meduloblastoma , Meduloblastoma/genética , Meduloblastoma/diagnóstico por imagen , Meduloblastoma/patología , Humanos , Neoplasias Cerebelosas/genética , Neoplasias Cerebelosas/diagnóstico por imagen , Neoplasias Cerebelosas/patología , Imagen por Resonancia Magnética/métodos , Niño , Femenino , Masculino , Adolescente , Inteligencia Artificial , Preescolar , China , Adulto Joven , Estados Unidos , Adulto , Pronóstico , Lactante , Aprendizaje Automático
2.
J Cancer Res Clin Oncol ; 149(15): 13943-13953, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37542548

RESUMEN

PURPOSE: To develop and validate a model that incorporates radiomics based on MRI scans and clinical characteristics to predict lymphovascular invasion (LVSI) in endometrial cancer (EC) patients. METHODS: There were 332 patients with EC enrolled retrospectively in this multicenter study. Radiomics score (Radscore) were computed using the valuable radiomics features. The independent predictors of LVSI were identified by univariate logistic analysis. Multivariate logistic regression was used to develop a clinical-radiomics predictive model. Based on the model, a nomogram was developed and validated internally and externally. The nomogram was evaluated with discrimination, calibration, decision curve analysis (DCA), and clinical impact curves (CIC). RESULTS: Three predictive models were constructed based on clinicopathological features, radiomic factors and a combination of them, and that the clinic-radiomic model performed best among the three models. Four independent factors comprised the clinical-radiomics model: dynamic contrast enhancement rate of late arterial phase (DCE2), deep myometrium invasion (DMI), lymph node metastasis (LNM), and Radscore. Clinical-radiomics model performance was 0.901 (95% CI 0.84-0.96) in the training cohort, 0.80 (95% CI 0.68-0.92) in the internal validation cohort, and 0.81 (95% CI 0.73-0.9) in the external validation cohort for identifying patients with LVSI, respectively. The model is used to develop a nomogram for clinical use. CONCLUSIONS: The MRI-based radiomics nomogram could serve as a noninvasive tool to predict LVSI in EC patients.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA